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Abstract
Graves’ophthalmopathy (GO) is characterized by expandedvolume of the orbital tissuesassociatedwith elevatedserum
levels of TSH receptor (TSHR) autoantibodies. Because previous studies have demonstrated evidence of adipogenesis
within the GO orbit, we sought to determine whether M22, a human monoclonal antibody directed against TSHR,
enhances adipogenesis in orbital ﬁbroblasts from patients with GO and, if so, to identify signaling mechanisms involved.
GO orbital ﬁbroblast cultures (nZ10) were treated for 10 days with bovine TSH (1 or 10.0 U/l) or M22 (1 or 10 ng/ml) in
serum-free adipocyte differentiation medium. Some cultures also received a phosphoinositide 3-kinase (PI3K) inhibitor or
an inhibitor of cAMP production. In other experiments, conﬂuent cultures (nZ8) were treated for between 1 and 30 min
with TSH (0.1–10.0 U/l) or M22 (0.1–100 ng/ml) with measurement of cAMP production or levels of phosphorylated AKT
(pAKT). We found levels of adiponectin, leptin, and TSHR mRNA to be increased in GO cultures treated for 10 days with
either M22 (2.6 mean fold G0.7; PZ0.03) or TSH (13.2G5.8-fold, PZ0.048). In other studies, M22 and TSH stimulated
cAMP production and pAKT levels in GO cells. Inhibition of PI3K activity during 10 days in culture decreased the levels of
M22-stimulatedmRNAencodingadiponectin(67G12%;PZ0.021),aswellasadiponectinandCCAAT/enhancer-binding
proteinaproteinlevels.Inconclusion,M22isapro-adipogenicfactorinGOorbitalpreadipocytes.Thisantibodyappearsto
actviathePI3Ksignalingcascade,suggestingthatinhibitionofPI3Ksignalingmayrepresentapotentialnoveltherapeutic
approach in GO.
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Introduction
Graves’ ophthalmopathy (GO) is an inﬂammatory
autoimmune disorder involving the fatty connective
tissue and the extraocular muscles within the bony orbit
(Bahn 2010). Many of the signs and symptoms of GO,
including proptosis and ocular congestion, result from
expansion of these tissues. While striking enlargement
of the extraocular muscles is evident in some patients,
and in others expanded volume of the orbital adipose
tissue predominates, the majority of patients show
expansion of both tissues (Forbes et al. 1986). While the
enlargement of the extraocular muscles is caused by an
accumulation of hydrophilic hyaluronan between the
muscle ﬁbers (Smith et al. 1989), the expanded orbital
adipose tissue volume is thought to be due to both
enhanced adipogenesis and the accumulation of
hyaluronan within these tissues (Kumar et al. 2004).
The formation of new fat cells within the orbit suggests
that resident preadipocytes are stimulated by some
GO-speciﬁc factor to undergo adipocyte differentiation.
Preadipocytes are a subpopulation (15–20%) of ﬁbro-
blasts cultured from the orbital adipose/connective
tissues capable of differentiating into mature adipocytes
(Kumar et al. 2004).
GO is closely associated with Graves’ hyperthyroid-
ism, a condition in which overproduction of thyroid
hormones by thyroid follicular cells is stimulated by
TSH receptor (TSHR) autoantibodies (TRAb). TSHR
mRNA and protein are detectable in both normal and
GO orbital adipose tissues (Feliciello et al. 1993,
Heufelder et al. 1993, Mengistu et al. 1994, Bahn et al.
1998), with the highest levels found in orbits of GO
patients having active disease (Wakelkamp et al. 2003).
Furthermore, levels of circulating TRAb correlate with
the clinical activity of the disease (Gerding et al. 2000)
and predict disease severity (Eckstein et al. 2006). Due
to the close clinical relationships between Graves’
hyperthyroidism and GO, and the presence of TSHR
in orbital tissues, it has been hypothesized that
155
Journal of Molecular Endocrinology (2011) 46, 155–163 DOI: 10.1530/JME-11-0006
0952–5041/11/046–155 q 2011 Society for Endocrinology Printed in Great Britain Online version via http://www.endocrinology-journals.org
This is an Open Access article distributed under the terms of the Society for Endocrinology’s Re-use Licence which permits unrestricted non-commercial use, distribution, and
reproduction in any medium, provided the original work is properly cited.circulating TRAb in Graves’ disease target TSHR within
the orbit and stimulate some of the histopathological
changes characteristic of the disease.
Most of the activities of the TSHR in thyrocytes are
mediated throughtheGsproteinsubunit,activatingthe
adenylyl cyclase/cAMP signaling cascade (Kimura et al.
2001). However, both TSH and some TRAb activate a
cAMP-independent cascade that increases phosphoino-
sitide 3-kinase (PI3K) activity with the subsequent
phosphorylation of AKT (Zaballos et al. 2008, Morshad
et al. 2009), a signaling pathway that plays a central role
in adipocyte differentiation (Xu & Liao 2004). We
undertook this study to determine whether M22, a high-
afﬁnity human monoclonal IgG1 l-chain stimulatory
antibody directed against a conformational TSHR
epitope (Sanders et al. 2003, 2004), or TSH stimulates
adipogenesisinorbitalpreadipocytesfrompatientswith
GO. We additionally studied the engagement of the
adenylyl cyclase and PI3K signaling cascades in orbital
preadipocytes to better understand the signaling
mechanisms that might be involved and exploited to
developnewtherapeuticstrategiesforpatientswithGO.
Materials and methods
Cell cultures
Orbital adipose tissue specimens were obtained from
euthyroid patients during the course of orbital
decompression surgery for severe GO. The study was
approved by the Mayo Clinic Institutional Review Board
and carried out according to IRB guidelines. The
orbital adipose/connective tissue specimens were
transported to the laboratory, minced, and placed
directly in plastic culture dishes, allowing ﬁbroblasts
to proliferate as described previously (Bahn et al. 1989).
Brieﬂy, cells were propagated in medium 199
containing 20% fetal bovine serum (FBS; HyClone
Laboratories, Inc., Logan, UT, USA), penicillin
(100 U/ml), and gentamycin (20 mg/ml) in a humidi-
ﬁed 5% CO2 incubator at 37 8C, and maintained in
75 mm
2 ﬂasks with medium 199 containing 10% FBS
and antibiotics.
Some studies were performed to determine the
impact on adipogenesis of M22, a stimulatory TRAb
derived from a patient with Graves’ hyperthyroidism
(M22; Kronus, Boise, ID, USA; # M22-1b; (Sanders et al.
2003, 2004), bovine TSH (Sigma Aldrich Co.; # T-8931),
or the insulin-like growth factor 1 (IGF1) analog, Des
1,3 (GroPep, Thebarton, Australia). For these studies,
conﬂuent orbital ﬁbroblasts were treated for 10 days
with bovine TSH (0.1–10.0 U/l and 1.7–170 nM), M22
(0.1–100 ng/ml and 0.67–670 pM), and IGF1 (Des 1,3
analog; 10 ng/ml; used as a positive control for
adipogenesis), or were untreated and cultured in
adipocyte differentiation medium (without insulin)
consisting of serum-free DMEM/Ham’s F-12 medium
(1:1; Sigma) supplemented with biotin (33 mM),
pantothenic acid (17 mM), transferrin (10 mg/ml), tri-
iodothyronine (T3)( 0 .2 nM), carbaprostacyclin
(cPGI2;0 .2 mM; Calbiochem, La Jolla, CA, USA), and,
for the ﬁrst 4 days only, dexamethasone (1 mM) and
isobutylmethylxanthine (IBMX; 0.1 mM). The media
were replaced every 3–4 days during the 10-day
differentiation period. Following the 10-day differen-
tiation period, cells were harvested and total RNA was
isolated for RT-PCR analysis of adipocyte-related genes.
In other experiments to assess the role of PI3K or
cAMP signaling in M22- or TSH-mediated adipogenesis,
conﬂuent orbital ﬁbroblasts were cultured for 10 days
in insulin-free adipocyte differentiation medium (as
mentioned above) containing the same treatments as
described earlier. In addition, some of the wells were
treated with the PI3K inhibitor LY294002 (10 or 50 mM)
throughout the 10-day differentiation period. To
determine whether insulin treatment might enhance
adipogenesis in M22-, TSH-, or IGF1-treated cells,
insulin (1 mM) was added to some of the wells.
Following the 10-day differentiation period, cells were
harvested and total RNA was isolated for RT-PCR
analysis of adipocyte-related genes.
For studies aimed at investigating the role of PI3K or
cAMP inM22 orTSH signaling (apartfrom theirimpact
on adipogenesis), orbital ﬁbroblasts were plated in
96-well dishes and grown to conﬂuence in the culture
medium as described earlier. In order to synchronize
the signaling event, cells were subsequently serum and
nutrient starved for 24 h. Experiments were carried out
for between 1 and 30 min in insulin-free adipocyte
differentiation medium. Cells received either no treat-
ment (negative control), bovine TSH (0.1–10.0 U/l
and 1.7–170 nM) or M22 (0.1–100 ng/ml and
0.67–670 pM). In addition, some of the wells were
treated with LY294002 (50 mM; SABiosciences;
Fresdrick, MD, USA), a speciﬁc inhibitor of PI3K, an
enzyme required for AKT phosphorylation or a cAMP-
dependent protein kinase peptide inhibitor (10 mM;
PKA #V5681; Promega), an inhibitor of cAMP pro-
duction. At the end of the treatment periods, cells or
supernatants were collected for the measurement of
AKT phosphorylation or cAMP production.
Real-time RT-PCR analyses
Total RNA was isolated from orbital cultures by the
RNeasy kit (Qiagen) according to the manufacturer’s
protocol. cDNA was synthesized using 750 ng total
RNA incubated with random hexamers, followed by
reverse transcription reaction in a 100 ml reaction
volume with 6.25 units of Multiscribe Reverse Tran-
scriptase (Applied Biosystems, Foster City, CA, USA).
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Oligonucleotide primers and TaqMan probes for
TSHR and GAPDH, and genes encoding the adipocyte
markers adiponectin (an adipocytokine exclusively
expressed and secreted by adipose tissue) and leptin
(synthesized and secreted primarily by adipocytes) were
purchased from Applied Biosystems. Expression of
GAPDH was used to correct for differences in the
amount of total RNA added to a reaction and to
compensate for different levels of inhibition during
reverse transcription of RNA and during PCR.
Quantitative PCR was performed in a 96-well optical
reaction plate. Ampliﬁcation reactions contained cDNA
equivalent of 5 ng total RNA, 900 nM forward and
reverse primers, and 250 nM probes in a volume of
25 ml using the Universal TaqMan 2X PCR Master mix
(Applied Biosystems). Reaction mixture, without the
cDNA, was used as no template control. The thermal
cycling conditions used were 2 min at 50 8C for optimal
AmpErase UNG activity, 10 min at 95 8C to activate
Amplitaq Gold DNA Polymerase, followed by 40 cycles
at 95 8C for 15 s and 60 8C for 1 min. The target genes
and GAPDH were ampliﬁed in separate wells. All
reactions were performed in duplicate in the ABI
PRISM 7700 Sequence Detector (Applied Biosystems),
and the data were pooled. The standard curve method
was used to quantify the expression of the various genes
and GAPDH rRNA in each sample. For each experi-
mental sample, a gene was considered not to be
expressed if ampliﬁcation was not detected by cycle
40. The normalized results were expressed as the ratio
of RNA (pg) of the target gene to RNA (pg) of GAPDH
rRNA. The expression level of each mRNA species
in the GO cell cultures was compared with that ins
untreated parallel cultures and expressed as fold
increase relative to control levels.
Measurement of AKT phosphorylation by ELISA
AKT protein phosphorylation induced by M22 or TSH
t r e a t m e n to fo r b i t a lc e l l sw a sm e a s u r e du s i n ga
commercial Cellular Activation of Signaling ELISA
(CASE) kit (AKT S473 (FE-001); SABiosciences
Corp.). This cell-based ELISA kit quantiﬁes the
amount of activated (phosphorylated serine 473) AKT
(phosphorylated AKT, pAKT) protein relative to total
AKT protein. Results are expressed as fold increase in
pAKT protein relative to parallel untreated cultures.
Western blotting
In order to assess AKTand pAKT protein levels in M22-
treated cells, conﬂuent orbital ﬁbroblasts were exposed
for 60 min to M22 (10 ng/ml), LY294002 (50 mM), M22
plus LY294002, or no treatment. In other experiments
designed to study the role of PI3K signaling in
M22-mediated adipogenesis, conﬂuent orbital ﬁbro-
blasts were cultured for 10 days in insulin-free adipocyte
differentiation medium containing M22 (10 ng/ml),
LY294002 (10 mM), M22 plus LY294002, or no treat-
ment. Cell protein was extracted using the complete
lysis-M, EDTA free protocol to extract total cytoplasmic
and nuclear protein (Roche # 04719964 001). Extracts
were subjected to electrophoresis on 4–12% Bis–Tris
gel, electrotransferred to polyvinylidene ﬂuoride mem-
brane, and blotted with primary antibody against pAKT,
AKT, adiponectin, CCAAT/enhancer-binding protein a
(C/EBPa; Cell Signaling Technology, Danvers, MA,
USA; # 9271S, 9272, 2789, 2295 respectively), or
GAPDH at 1:1000 dilution. The appropriate secondary
IgG-HRP-linked conjugate (Cell Signaling, # 7074) at
1:2000 dilution was applied, followed by enhanced
chemiluminescence detection.
Measurement of cAMP production
Levels of cAMP were measured by Cyclic-AMP Assay
(R&D Systems, Minneapolis, MN, USA; #KGE002B)
using a polyclonal antibody that competitively bound
cAMP in the standards or sample supernates. Results
are expressed as fold increase in cAMP production
relative to parallel untreated cultures.
Statistical analyses
The paired t-test was used to evaluate the signiﬁcance of
differences in means for continuous variables, with
values presented as the meanGS.D. The Mann–Whitney
Rank Sum test was used to assess differences between
the groups. A P value of %0.05 was considered to be
statistically signiﬁcant.
Results
M22 and TSH enhance adipogenesis in GO
orbital cultures
Treatment of GO orbital cultures (nZ10) with M22 (1.0
or 10 ng/ml) during culture for 10 days in insulin-free
differentiation medium resulted in increased adiponec-
tin mRNA levels relative to control cultures at 10 ng/ml
(2.6G0.7-fold; PZ0.03), with M22 at 1.0 ng/ml not
reaching signiﬁcance (PZ0.24; Fig. 1A). Treatment
with TSH (1 or 10 U/l) resulted in increased adipo-
nectin mRNA levels at both doses (1 U/l TSHZ9.5
G5.0-fold, PZ0.023; 10 U/l TSHZ13.2G5.8-fold,
PZ0.048; Fig. 1A). Positive control cultures containing
IGF1 (Des 1,3 analog; 10 nM) showed elevated levels of
adiponectin mRNA (152.4G63.4-fold, PZ0.025; Fig. 1A).
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i n gt r e a t m e n tw i t hM 2 2( 1 n g / m l Z1.8G0.2-fold,
PZ0.002; 10 ng/mlZ3.4-foldG0.6, PZ0.001), TSH
(1 U/lZ7.8G2.4-fold, PZ0.019; 10 U/lZ7.9G2.0-
fold, PZ0.007), or the IGF1 analog (11.7G3.6-fold,
PZ0.015; Fig. 1B). Similarly, TSHR mRNA levels were
elevated in cultures treated with M22 (1 ng/mlZ
3.6G0.4-fold, P!0.001; 10 ng/mlZ3.5G0.8-fold,
PZ0.007), TSH (1 U/lZ1.8G0.4-fold, PZ0.078;
10 U/lZ3.2G0.7-fold, PZ0.008), and IGF1 analog
(8.5G1.8-fold, PZ0.001; Fig. 1C). Finally, while we
found that the addition of insulin (1 mM) to M22- or
TSH-treated cultures and control cultures enhanced
the overall magnitude of adipogenesis in all cultures,
the fold increase in adipogenesis was not different from
that found in insulin-free cultures (data not shown).
Visual inspection of cells cultured for 10 days in
insulin-free adipocyte differentiation medium and
stainedwithoilred-Orevealedclearlyincreasedstaining
in IGF1 (Des 1,3 analog)-treated orbital cultures
(Fig. 2A) compared with control cultures (Fig. 2B).
In cultures treated with either M22 (10 ng/ml) or TSH
(10 U/l), small foci of increased oil red-O staining
were apparent on visual inspection (Fig. 2C and D
respectively).
M22 and TSH stimulate dose- and time-dependent
increases in AKT protein phosphorylation
GO orbital ﬁbroblast cultures (nZ8) treated with M22
(0.1–100 ng/ml) or TSH (0.001–10 U/l) for 5 min
showed a dose-dependent increase in pAKT (assessed
using an ELISA) that was signiﬁcant compared
with parallel control cultures beginning at 0.1 ng/ml
for M22 and at 0.1U / l f o r T S H ( Fig. 3). In
addition, treatment of orbital cultures (nZ8) for 1, 5,
10, or 30 min with either M22 (5 ng/ml) or TSH
(10 U/l) showed a time-dependent increase in pAKT
protein that was signiﬁcant at each time point
for each treatment compared with parallel control
cultures (Fig. 4).
M22-stimulated increase in AKT protein phosphory-
lation is inhibited by a speciﬁc PI3K inhibitor
Treatment of GO orbital ﬁbroblast cultures (nZ8) for
1, 5, 10, or 30 min with M22 (5 ng/ml) in combination
with the speciﬁc PI3K inhibitor LY294002 (50 mM)
showed decreased pAKT protein levels at each time
point relative to cultures treated with M22 alone,
reaching signiﬁcance at 30 min (Fig. 4). While there
was a trend toward decreased pAKT protein levels in
TSH-treated cultures exposed to LY294002 compared
with those treated with TSH alone, this did not reach
signiﬁcance. Western blotting of protein extracts from
GO orbital ﬁbroblast cultures (nZ2) treated for 60 min
with M22 (5 ng/ml), M22 plus LY294002, or LY294002
alone showed increased AKT phosphorylation in
cultures treated with M22 alone and inhibition of this
effect in cells treated with both M22 and LY294002 (Fig.5).
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Figure 1 Effect of treatment with M22 (1.0 or 10 ng/ml), TSH (1 or
10 U/l), or the positive control IGF1 Des 1,3 analog (10 ng/ml) on
adipogenesis of GO orbital preadipocytes (nZ10) cultured for
10 days in insulin-free differentiation medium. Results are
expressed as meanGS.D. fold increase (relative to control
untreatedcultures)inmRNAlevelsencodingadipocyte-associated
genes; A) adiponectin; B) leptin; and C) TSH receptor. *P!0.05.
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shows increased AKT phosphorylation in cells treated
for 60 min with IGF1 (Des 1,3 analog; 10 ng/ml) and
inhibition of this effect in cells treated with both IGF1
and LY294002.
M22-enhanced adipogenesis is inhibited by a speciﬁc
PI3K inhibitor
We found a decrease in adiponectin mRNA levels in
orbital cultures (nZ4) treated during the entire 10-day
differentiation period with both M22 (10 ng/ml) and
LY294002 (50 mM) compared with cultures treated with
M22 alone (67G12.2%, PZ0.021; Fig. 6). At the same
time, levels of the housekeeping gene GAPDH did not
change during the 10-day incubation period in either
set of cultures, remaining at w19 cycles throughout. In
other experiments, cultures treated with both M22 and
LY294002 showed levels of adiponectin mRNA that
were approximately tenfold than those found in
cultures treated with LY294002 alone (data not
shown). While cultures treated with both TSH (10 U/l)
and LY294002 showed a trend toward diminished
adiponectin mRNA levels compared with TSH-treated
cultures, this did not reach signiﬁcance (42.7G6.0%).
We also found a decrease in protein levels for
adiponectin (an adipocyte-speciﬁc protein) and
C/EBPa (an adipocyte-related protein) in cultures
treated during the entire 10-day differentiation period
with both M22 (10 ng/ml) and LY294002 (at the lower
dose of 10 mM) compared with cultures treated with
M22 alone (Fig. 7). These studies also demonstrated an
increase in both adiponectin and C/EBPa protein
levels in M22-treated cultures compared with untreated
cultures, conﬁrming the stimulation of adipogenesis by
M22 on the protein level (Fig. 7).
Figure 2 Oil red-O staining of orbital adipocytes that were cultured for 10 days in insulin-
free adipocyte differentiation medium containing A) IGF1 (Des 1,3 analog; 10 ng/ml);
B) untreated; C) M22 (10 ng/ml); or D) TSH (10 U/l).
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to parallel untreated cultures. *P!0.05.
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GO orbital ﬁbroblast cultures (nZ8) treated for
between 1 and 30 min with M22 (0.1–100 ng/ml; equi-
valent to 0.001–1 mg/ml) or bovine TSH (0.01–10 U/l)
showed a dose-dependent increase in cAMP production
that was signiﬁcant for M22 at 10 ng/ml and for TSH at
1 U/l (data not shown). In addition, treatment of
cultures for 1, 5, 10, or 30 min with M22 (100 ng/ml)
or TSH (10 U/l) showed a time-dependent increase in
cAMP production (data not shown). While there was a
trend toward decreased adiponectin mRNA levels in
cultures treated for 10 days with either M22 or TSH and
the cAMP-dependent protein kinase peptide inhibitor
PKA #V5681 (44G8 and 24G7% respectively), this did
not reach signiﬁcance (data not shown).
Discussion
M22 is a potent stimulatory human monoclonal
autoantibody to TSHR that also possesses powerful
TSH-binding inhibiting activity (Sanders et al. 2003,
2004). Our ﬁnding that this antibody is capable of
enhancing adipocyte differentiation in cultured human
orbital ﬁbroblast cultures (containing w15–20% pre-
adipocytes, deﬁned as cells capable of differentiating
into mature adipocytes) is, to our knowledge, the ﬁrst
demonstration of an autoantibody being pro-adipo-
genic in any cell system. That TSH is a pro-adipogenic
factor in the conversion of mouse embryonic stem cells
into adipocytes has been reported by Lu & Lin (2008).
These investigators found that treatment with TSH
(1 U/l) increased adipogenesis in the absence of the
adipogenic factors insulin, T3, and the peroxisome
proliferator-activated receptor-g (PPARg) agonist rosi-
glitazone. They found elevated levels of mRNA
encoding early to intermediate adipocyte marker
genes, including C/EBPb and PPARg but did not
measure genes associated with terminal adipocyte
differentiation. However, they demonstrated a time-
dependent increase in lipid accumulation (oil red-O
staining of lipid droplets) in these cells, suggesting that
terminal differentiation was complete. They also found
an increase in TSHR mRNA and immunoﬂuorescent
protein expression in embryonic cells containing lipid
droplets, as well as an increase in TSH-stimulated cAMP
production, as was reported in earlier studies showing
enhanced TSHR expression in differentiated orbital
adipocytes (Valyasevi et al. 1999, Crisp et al. 2000). Our
studies were performed in culture medium that also did
not contain insulin. However, in contrast to the studies
by Lu & Lin, our cultures did contain T3 and IBMX
because we have been unable to detect adipogenesis in
M22- or TSH-treated cultures in the absence of these
adipogenic factors. This suggests that while M22 and
TSH are pro-adipogenic factors in our system, they
require the presence of cAMP and other factors to
activate the process.
In a study by Zhang et al. (2006), activation of TSHR
by introduction of an activating mutant receptor into
human orbital preadipocytes using retroviral vectors
resulted in an increase in early adipocyte differen-
tiation, as demonstrated by two- to eightfold elevations
in levels of the early to intermediate markers, C/EBPb
and PPARg. In these studies, levels of mRNA encoding
lipoprotein lipase (LPL; a late adipocyte marker) were
at the limit of detection. Expression of the activating
TSHR also produced a two- to sixfold increase in basal
cAMP levels and 4- to 16-fold cAMP elevation in TSH-
treated cells. While no obvious oil red-O staining was
apparent on visualization in mutant or WT TSHR-
expressing orbital cells, quantitation revealed measur-
able staining with somewhat higher levels in the mutant
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Figure 4 Effect of 1, 5, 10, or 30 min treatment with M22 (5 ng/ml;
ﬁlled circles), TSH (10 U/l; open circles), or agent in combination
with the speciﬁc PI3K inhibitor LY294002 (50 mM) on phosphory-
lated AKT (pAKT) protein levels in GO orbital ﬁbroblast cultures
(nZ8). ELISA results are expressed as meanGS.E.M. fold
increase in pAKT levels (solid lines) relative to parallel untreated
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Figure 5 Western blots showing total and phosphorylated AKT
(pAKT)andGAPDHproteinbandsinconﬂuentGOorbitalﬁbroblast
cultures exposed to the indicated treatments for 60 min. Left: 1) no
treatment; 2) M22 (10 ng/ml); 3) M22 plus LY294002 (50 mM); or 4)
LY294002 alone. Right: 1) no treatment; 2) IGF1 (Des 1,3 analog
10 ng/ml; 3) IGF1 plus LY294002; or 4) LY294002 alone.
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while the basal lipid content of activated cells was
higher, it failed to increase in response to a PPARg
agonist, suggesting that TSHR activation renders
these transfected cells refractory to PPARg-induced
adipogenesis. Furthermore, while the mutant TSHR-
containing cultures subjected to adipocyte differen-
tiation medium for 10 days showed somewhat elevated
levels of early and intermediate stages of adipocyte
differentiation compared with the WT-TSHR-trans-
fected cells, they failed to show elevated levels of LPL.
In our studies, in contrast to those of Zhang et al.
(2006), we found clusters of lipid-containing vacuoles,
evidence of late-adipocyte gene expression (increased
levels of adiponectin, leptin, and TSHR mRNA) in our
cultures treated with either M22 or TSH, suggesting
the presence of mature adipocytes. Differences found
in the extent of adipogenesis between our TSH- or
M22-stimulated cells and the TSHR-transfected orbital
preadipocytes used in the Zhang study may be
explained by changes in the adipogenic potential of
the latter cells owing to the transfection itself,
rendering them refractory to PPARg activation and
thus unable to differentiate into mature fat cells. In a
subsequent study using the same system, Zhang et al.
(2009a) reported that Gsa (cAMP) signaling inhibits
and that Gbg (PI3K) signaling enhances the later stages
of adipogenesis. As our TSH- or M22-treated cultures
expressed higher levels of TSHR than untreated
cultures, and undifferentiated GO orbital ﬁbroblasts
express only very low levels of TSHR (Heufelder et al.
1993), it is possible that TSH and M22 act to upregulate
TSHR expression, and that this in turn further
increases PI3K activity and results in enhanced
adipogenesis. In another study, Zhang et al. (2009b)
found increased production of hyaluronan by their
mutant TSHR-transfected GO orbital preadipocytes, as
well as by GO orbital preadipocytes treated with two
other TRAb (one stimulatory and the other neutral),
suggesting that TSHR activation with PI3K signaling
may contribute to the orbital accumulation of hyalur-
onan observed in GO.
In a recent study characterizing TRAb-induced
signaling cascades, Morshad et al. (2009) have assessed
the interaction of M22 with the TSHR in the Fisher Rat
Thyroid cell Line (FRTL-5). They demonstrated 1.5- to
2.5-fold stimulation of cAMP as well as dose- and time-
dependent increases in pAKT in FRTL-5 cells treated
with either M22 or bovine TSH. While our ﬁndings are
similar and the bovine TSH doses we used were
comparable, our doses of M22 were 10- to 100-fold
lower. Therefore, it appears that GO orbital preadipo-
cytes and FRTL-5 cells are similarly sensitive to TSH or
M22 in terms of enhanced cAMP production and to
TSH in its augmentation of pAKT levels. However, our
results suggest that orbital preadipocytes may be more
sensitive to the effect of M22 on pAKT levels than are
FRTL-5 cells.
The differentiation of precursor cells (preadipocytes)
into mature adipocytes is controlled by a complex
network of signaling pathways, closely regulated by
transcription factors, including members of the C/EBP
and PPAR families (Rosen & MacDougald 2006). The
initiation of adipocyte differentiation appears to
require cAMP, which generally functions through the
classical protein kinase A pathway to phosphorylate and
activate key regulatory transcription factors (Engelman
et al. 1999). Terminal adipocyte differentiation is
promoted by the activity of several kinases, particularly
kinases of the PI3K/AKT pathway and those activating
p38 mitogen-activated protein kinases (Kohn et al.
1996), and results in the synthesis of adipocyte-secreted
products, including adiponectin (the most abundant
transcript in human adipose tissue) and leptin
(Gregiore et al. 1998).
We found that treatment of GO orbital preadipocytes
with the speciﬁc PI3K inhibitor LY294002 in com-
bination with M22 decreases the levels of adiponectin
mRNA as well as of adiponectin and C/EBPa protein
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Figure 6 Effect of M22 (10 ng/ml) or TSH (10 U/l) and the speciﬁc
PI3K inhibitor LY294002 on adiponectin mRNA levels in GO
orbital preadipocytes (nZ8) cultured for 10 days in insulin-free
differentiation medium. Results are expressed as meanGS.D. fold
increase in adiponectin mRNA levels relative to control untreated
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Figure 7 Western blots showing C/EBPa (top), adiponectin
(middle), and GAPDH (bottom) protein bands in conﬂuent GO
orbital ﬁbroblast cultures exposed throughout 10 days in culture to
the indicated treatments. Lane 1) no treatment; 2) LY294002
(10 mM); 3) M22 (10 ng/ml); 4) M22 plus LY294002.
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there was a similar trend observed in TSH-treated
cultures, this did not reach signiﬁcance. These ﬁndings
suggest that the observed stimulatory effect of M22 on
adipogenesis in these cells may involve the PI3K
pathway. However, because inhibition of adipogenesis
by LY294002 was not complete andcultures treatedwith
the cAMP-dependent protein kinase peptide inhibitor
also showed some degree of inhibition (albeit not
signiﬁcant in magnitude), it is likely that the cAMP
pathway also plays a role in adipogenesis in these cells.
AKT is an important mediator of insulin-activated
IGF1 receptor (IGF1R) signaling that plays a central
role in the regulation of adipocyte differentiation (Xu
& Liao 2004). As expected, we found the IGF1 analog
Des 1,3 to be a potent stimulator of adipogenesis in GO
orbital preadipocytes. Recent studies have suggested
that autoantibodies directed against the IGF1R may
circulate in patients with GO, recognize the receptor on
orbital preadipocytes, and initiate some of the tissue
changes characteristic of the disease (Smith & Hoa
2004). In addition, evidence suggests that physical and
functional relationships may exist between IGF1R and
TSHR in orbital ﬁbroblasts (Smith 2003). It is therefore
possible that these relationships may facilitate the
engagement of the PI3K/AKT pathway by autoanti-
bodies in GO directed against either or both of these
receptors. Our results suggest, however, that stimulatory
TRAb are themselves capable of enhancing orbital
adipogenesis in GO without implicating the presence of
autoantibodies-directed against IGF1R.
The relevance of our ﬁndings to Graves’ hyper-
thyroidism and GO stems from the fact that the TRAb
used in these studies was a human monoclonal
stimulatory TRAb (Sanders et al. 2004b), while the
cells were derived from the orbits of patients with GO.
The overproduction of thyroid hormones by thyroid
follicular epithelial cells in Graves’ disease is caused by
circulating stimulatory autoantibodies targeting TSHR
(Rapoport et al. 1998). Although enhanced adipogen-
esis within the GO orbit contributes to expansion of the
orbital adipose tissues and results in many of the clinical
manifestations of the disease (Bahn 2010), the cause of
this tissue remodeling is not understood. Our ﬁnding
that a TRAb stimulates human orbital preadipocytes to
differentiate into mature adipocytes suggests that
TSHR-directed autoantibodies in Graves’ disease may
represent a link between Graves’ hyperthyroidism and
its ocular manifestations.
The M22 antibody used in our studies is considered
‘stimulatory’, because it is similar to TSH in that it
stimulates thyrocytes via Gas-cAMP/protein kinase
A/ERK-coupled signaling network. This antibody is
also capable of engaging Gaq subunits in thyrocytes
that activate phospholipase C (Morshad et al. 2009).
Other TSHR-directed antibodies reduce TSH action
at the TSHR (so called ‘blocking antibodies’) or have
no inﬂuence on TSH binding (neutral antibodies).
Some of these antibodies have recently been shown to
use signaling cascades not activated by TSH (Morshad
et al. 2009). We found M22 to be capable of engaging
both G protein subunits in orbital ﬁbroblasts, as
evidenced by its stimulation of both cAMP produc-
tion and levels of pAKT. It may be that the variable
clinical manifestations of GO, and the occurrence of
‘euthyroid’ GO, are attributable to the activation
of various signaling networks and downstream effectors
in orbital ﬁbroblasts by the stimulatory, inhibitory, and
neutral TSHR antibodies known to be circulating in
patients with Graves’ disease.
In conclusion, we present the novel ﬁnding that M22
is a pro-adipogenic factor in GO orbital preadipocytes,
and that this occurs through PI3K pathway activation at
very low concentrations of the antibody. These ﬁndings
suggest a mechanism whereby particular TRAb in
Graves’ disease may play a role in the development of
the ocular manifestations of the disease. In addition,
they point toward the PI3K signaling pathway as a
potential target for novel GO therapies. Better under-
standing of the various signaling cascades activated by
individual TRAb in GO orbital ﬁbroblasts will improve
our understanding of the development and the
heterogeneous nature of the extrathyroidal mani-
festations of Graves’ disease, and may aid in the
development of novel therapies for GO.
Declaration of interest
The authors declare that there is no conﬂict of interest that could be
perceived as prejudicing the impartiality of the research reported.
Funding
This work was supported by the National Institute of Diabetes,
Digestive and Kidney Diseases (grant number DK77814).
References
Bahn RS 2010 Mechanisms of disease: Graves’ ophthalmopathy.
New England Journal of Medicine 362 726–738. (doi:10.1056/
NEJMra0905750)
Bahn RS, Gorman CA, Johnson CM & Smith TJ 1989 Presence of
antibodies in the sera of patients with Graves’ disease recognizing a
23 kilodalton ﬁbroblast protein. Journal of Clinical Endocrinology and
Metabolism 69 622–628. (doi:10.1210/jcem-69-3-622)
Bahn RS, Dutton CM, Natt N, Joba W, Spitzweg C & Heufelder AE 1998
Thyrotropin receptor expression in Graves’ orbital adipose/con-
nective tissues: potential autoantigen in Graves’ ophthalmopathy.
Journal of Clinical Endocrinology and Metabolism 83 998–1002.
(doi:10.1210/jc.83.3.998)
Crisp M, Starkey K, Lane C, Ham J & Ludgate M 2000 Adipogenesis in
thyroid eye disease. Investigative Ophthalmology and Visual Science 41
3249–3255.
S KUMAR and others . Adipogenesis in Graves’ orbital preadipocytes 162
Journal of Molecular Endocrinology (2011) 46, 155–163 www.endocrinology-journals.orgEckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S,
Heckmann C, Esser J & Morgenthaler NG 2006 Thyrotropin
receptor autoantibodies are independent risk factors for Graves’
ophthalmopathy and help to predict severity and outcome of
the disease. Journal of Clinical Endocrinology and Metabolism 91
3464–3470. (doi:10.1210/jc.2005-2813)
Engelman JA, Berg AH, Lewis RY, Lin A, Lisanti MP & Scherer PE 1999
Constitutively active mitogen-activated protein kinase kinase 6
(MKK6) or salicylate induces spontaneous 3T3-L1 adipogenesis.
Journal of Biological Chemistry 274 35630–35638. (doi:10.1074/jbc.
274.50.35630)
Feliciello A, Porcellini A, Ciullo I, Bonavolonta G, Avvedimento EV &
Fenzi G 1993 Expression of thyrotropin-receptor mRNA in healthy
and Graves’ disease retro-orbital tissue. Lancet 342 337–338.
(doi:10.1016/0140-6736(93)91475-2)
Forbes G, Gorman CA, Brennan MD, Gehring DG, Ilstrup DM &
Earnest Ft 1986 Ophthalmopathy of Graves’ disease: computerized
volume measurements of the orbital fat and muscle. AJNR. American
Journal of Neuroradiology 7 651–656.
Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM
& Prummel MF 2000 Association of thyrotrophin receptor anti-
bodies with the clinical features of Graves’ ophthalmopathy. Clinical
Endocrinology 52 267–271. (doi:10.1046/j.1365-2265.2000.00959.x)
Gregiore F, Smas C & Sul H 1998 Understanding adipocyte
differentiation. Physiological Reviews 78 783–809.
Heufelder AE, Dutton CM, Sarkar G, Donovan KA & Bahn RS 1993
Detection of TSH receptor RNA in cultured ﬁbroblasts from
patients with Graves’ ophthalmopathy and pretibial dermopathy.
Thyroid 3 297–300. (doi:10.1089/thy.1993.3.297)
Kimura T, Van K, Golstein J, Fusco A, Dumont J & Roger P 2001
Regulation of thyroid cell proliferation by TSH and other factors: a
critical evaluation of in vitro models. Endocrine Reviews 22 631–656.
(doi:10.1210/er.22.5.631)
Kohn A, Summers S, Birnbaum M & Roth R 1996 Expression of a
constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes
stimulates glucose uptake and glucose transporter 4 translocation.
Journal of Biological Chemistry 271 31372–31378. (doi:10.1074/jbc.
271.49.31372)
Kumar S, Coenen MJ, Scherer PE & Bahn RS 2004 Evidence for
enhanced adipogenesis in the orbits of patients with Graves’
ophthalmopathy. Journal of Clinical Endocrinology and Metabolism 89
930–935. (doi:10.1210/jc.2003-031427)
Lu M & Lin RY 2008 TSH stimulates adipogenesis in mouse embryonic
stem cells. Journal of Endocrinology 196 159–169. (doi:10.1677/JOE-
07-0452)
Mengistu M, Lukes YG, Nagy EV, Burch HB, Carr FE, Lahiri S &
Burman KD 1994 TSH receptor gene expression in retroocular
ﬁbroblasts. Journal of Endocrinological Investigation 17 437–441.
Morshad SA, Latif R & Davies TF 2009 Characterization of thyrotropin
receptor antibody-induced signaling cascades. Endocrinology 150
519–529. (doi:10.1210/en.2008-0878)
Rapoport B, Chazenbalk GD, Jaume JC & McLachlan SM 1998 The
thyrotropin (TSH) receptor: interaction with TSH and autoanti-
bodies. Endocrine Reviews 19 673–716. (doi:10.1210/er.19.6.673)
Rosen ED & MacDougald OA 2006 Adipocyte differentiation from the
inside out. Nature Reviews. Molecular Cell Biology 7 885–896.
(doi:10.1038/nrm2066)
Sanders J, Evans M, Premawaradhana L, Depraetere H, Jeffreys J,
Richards T, Furmaniak J & Smith B 2003 Human monoclonal
thyroid stimulating autoantibody. Lancet 362 126–128. (doi:10.
1016/S0140-6736(03)13866-4)
Sanders J, Jeffreys J, Depraetere H, Evans M, Richards T, Kiddie A,
Brereton K, Premawardhana LD, Chirgadze DY, Nunez Miguel R
et al. 2004 Characteristics of a human monoclonal autoantibody to
the thyrotropin receptor: sequence structure and function. Thyroid
14 560–570. (doi:10.1089/1050725041692918)
Smith TJ 2003 The putative role of ﬁbroblasts in the pathogenesis of
Graves’ disease: evidence for the involvement of the insulin-like
growth factor-1 receptor in ﬁbroblast activation. Autoimmunity 36
409–415. (doi:10.1080/08916930310001603000)
Smith TJ & Hoa N 2004 Immunoglobulins from patients with Graves’
disease induce hyaluronan synthesis in their orbital ﬁbroblasts
through the self-antigen, insulin-like growth factor-I receptor.
Journal of Clinical Endocrinology and Metabolism 89 5076–5080.
(doi:10.1210/jc.2004-0716)
Smith TJ, Bahn RS & Gorman CA 1989 Connective tissue,
glycosaminoglycans, and diseases of the thyroid. Endocrine Reviews
10 366–391. (doi:10.1210/edrv-10-3-366)
Valyasevi RW, Erickson DZ, Harteneck DA, Dutton CM, Heufelder AE,
Jyonouchi SC & Bahn RS 1999 Differentiation of human orbital
preadipocyte ﬁbroblasts induces expression of functional thyro-
tropin receptor. Journal of Clinical Endocrinology and Metabolism 84
2557–2562. (doi:10.1210/jc.84.7.2557)
Wakelkamp IM, Bakker O, Baldeschi L, Wiersinga WM & Prummel MF
2003 TSH-R expression and cytokine proﬁle in orbital tissue of
active vs. inactive Graves’ ophthalmopathy patients. Clinical
Endocrinology 58 280–287. (doi:10.1046/j.1365-2265.2003.01708.x)
Xu J & Liao K 2004 Protein kinase B/AKT 1 plays a pivotal role in
insulin-like growth factor-1 receptor signaling induced 3T3-L1
adipocyte differentiation. Journal of Biological Chemistry 279
35914–35922. (doi:10.1074/jbc.M402297200)
Zaballos M, Garcia B & Santisteban P 2008 G beta gamma dimers
released in response to thyrotropin activate phosphoinositide
3-kinase and regulate gene expression in thyroid cells. Molecular
Endocrinology 22 1183–1199. (doi:10.1210/me.2007-0093)
Zhang L, Baker G, Janus D, Paddon CA, Fuhrer D & Ludgate M 2006
Biological effects of thyrotropin receptor activation on human
orbital preadipocytes. Investigative Ophthalmology and Visual Science
47 5197–5203. (doi:10.1167/iovs.06-0596)
Zhang L, Paddon C, Lewis MD, Grennan-Jones F & Ludgate M 2009a
Gsalpha signalling suppresses PPARgamma2 generation and
inhibits 3T3L1 adipogenesis. Journal of Endocrinology 202 207–215.
(doi:10.1677/JOE-09-0099)
Zhang LS, Greyner HJ, Mummert ME & Petroll WM 2009b
Development of a hyaluronan bioconjugate for the topical
treatment of melanoma. Journal of Dermatological Science 55 56–59.
(doi:10.1016/j.jdermsci.2009.02.014)
Received in ﬁnal form 10 January 2011
Accepted 14 February 2011
Made available online as an Accepted Preprint 14 February 2011
Adipogenesis in Graves’ orbital preadipocytes . S KUMAR and others 163
www.endocrinology-journals.org Journal of Molecular Endocrinology (2011) 46, 155–163